Assessment Algorithm and Objects of Study
The diagnosis of immune disorders relies on a clear algorithm: first, an immunological history is taken, followed by laboratory investigation of key immune components, and finally, a specific pathology is verified. Laboratory testing employs a tiered (two-stage) approach.
All tests are classified according to cellular and humoral targets:
- Cellular branch of adaptive immunity: T-lymphocyte populations are analyzed.
- Humoral branch of adaptive immunity: B-lymphocyte status and antibody (immunoglobulin) concentrations are evaluated.
- Cellular branch of innate immunity: The activity of macrophages (phagocytes), NK cells, and other factors is investigated.
- Functional molecules: The levels of cytokines and other soluble mediators are determined.
The primary biological material is peripheral blood. In complex cases, additional materials are used: mucous membrane secretions, tear fluid, and cerebrospinal fluid (liquor).
Age-Related Dynamics of Parameters
The main tool for studying cell populations is flow cytometry. This method evaluates absolute and relative (percentage ratio) parameters of cells carrying specific receptors—CD markers—on their surface.
When interpreting results, it is important to consider age-related dependencies, as reference values are not static. For example, during the transition from preschool age to adulthood, the following pattern is observed:
- T lymphocytes (CD3): Relative count increases from 62–69% (up to 6 years) to 66–76% in adults.
- T helper cells (CD4): The population increases from 30–40% (up to 17 years) to 38–46%.
- Cytotoxic T lymphocytes (CD8): Their share smoothly increases from 25–32% to 31–40%.
- B lymphocytes (CD19): Unlike T cells, their count gradually decreases from 24% in childhood to 13% in adulthood.
Humoral Immunity and Its Variability
To assess the humoral branch, the concentration of major immunoglobulin classes in blood serum is determined. In healthy adults, reference values are:
- IgG: 6.5–13.5 g/L;
- IgM: 0.55–3.5 g/L;
- IgA: 0.7–3.15 g/L.
Other antibody classes (such as IgE) are normally virtually undetectable in the bloodstream. A sharp increase in IgE serves as a reliable marker for allergic pathology.
It is important to remember that parameters have a wide range of normal values. They vary significantly under the influence of hormonal shifts, environmental factors, and other causes, which can make interpretation difficult. During analysis, the physician typically concludes one of three states: no reliable changes, minor shifts in several parameters, or significant alterations in immune status.
Advanced Evaluation of Immune Response Stages
If basic tests are insufficient, an expanded immunogram is used, detailing the performance of protective systems at all stages of the process:
- Antigen recognition: T-helper function is evaluated (expression of MHC II molecules), quantitative analysis of CD4+ and CD8+ cells is performed, and activation markers (expression of CD25, CD69, synthesis of pro-inflammatory cytokines) are identified.
- Differentiation: Identification of specific CD markers at various stages of lymphocyte maturation.
- Effector phase: Analysis of cellular cytotoxicity and the production of effector molecules.
- Immune memory: Determination of specific immunoglobulin levels.
- Immunoregulation: Assessment of the balance of pro- and anti-inflammatory cytokines, determination of regulatory T cells (T-reg).
- Apoptosis: The final stage of the response, studied by assessing caspase activity and identifying apoptotic bodies (via the TUNEL method).
Personalized Diagnostics and Therapy
Ordering a full panel of immunological tests is excessive; test selection must always be based on the clinical picture. This differential approach optimizes diagnostics:
- In bacterial infections, it is appropriate to examine the B-cell branch of immunity.
- In viral infections, the emphasis shifts to the cellular branch (innate and adaptive), as well as the interferon status.
Obtained laboratory data allow specialists to precisely select immunotropic therapy and minimize the risk of side effects for the patient.